Home > Insider Trading > Filing (0001567619-21-016927)

Filing Details

Accession Number:: 0001567619-21-016927
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-09-09 19:24:12
Reporting Period:: 2021-09-07

Accepted Time:: 2021-09-09 19:24:12
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1676725	Ideaya Biosciences Inc.	IDYA	Pharmaceutical Preparations (2834)	474268251

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1777415	P. Michael Dillon	C/O Ideaya Biosciences, Inc. 7000 Shoreline Court, Suite 350 South San Francisco CA 94080	Svp, Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-09-07	116	$4.31	78,905	No	4	M	Direct
Common Stock	Disposition	2021-09-07	116	$27.46	78,789	No	4	S	Direct
Common Stock	Acquisiton	2021-09-08	7,071	$4.31	85,860	No	4	M	Direct
Common Stock	Acquisiton	2021-09-08	4,313	$11.08	90,173	No	4	M	Direct
Common Stock	Disposition	2021-09-08	11,184	$27.41	78,989	No	4	S	Direct
Common Stock	Disposition	2021-09-08	200	$27.67	78,789	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-09-07	116	$0.00	116	$4.31
Common Stock	Stock Option (Right to Buy)	Disposition	2021-09-08	7,071	$0.00	7,071	$4.31
Common Stock	Stock Option (Right to Buy)	Disposition	2021-09-08	4,313	$0.00	4,313	$11.08

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
66,119	2028-02-26	No	4	M	Direct
59,048	2028-02-26	No	4	M	Direct
24,937	2029-03-13	No	4	M	Direct

Footnotes

The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
This transaction was executed in multiple trades in prices ranging from $27.45 to $27.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $26.56 to $27.52, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
25% of the shares subject to the option vest on the first anniversary measured from February 19, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.